Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HGF | P14210 | 1/20 | 0.38 |
| ▸ | MST1R | Q04912 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915575 | 0.89 | GRK2 (0.45) | S1PR5ERN1MAPK14METHGF | |
| SCHEMBL3923436 | 0.89 | S1PR5 (0.42) | SMN1; SMN2TSHRKMT2AS1PR5ERN1 | |
| SCHEMBL3911319 | 0.88 | SCD (0.43) | MEN1KMT2AFFAR1PPARDS1PR5 | |
| SCHEMBL3911190 | 0.88 | S1PR5 (0.43) | FFAR1PPARDS1PR5ERN1MAPK14 | |
| SCHEMBL3912908 | 0.88 | MAPK14 (0.43) | SMN1; SMN2TSHRFFAR1PPARDS1PR5 | |
| SCHEMBL3917605 | 0.85 | CYP11B1 (0.47) | SMN1; SMN2TSHRS1PR5CYP3A4CYP2C9 | |
| SCHEMBL3917400 | 0.85 | MRGPRX4 (0.43) | S1PR5CYP3A4CYP2C9MAPK14GRK2 | |
| SCHEMBL3105830 | 0.85 | CYP11B1 (0.44) | S1PR5CYP3A4CYP2C9MAPK14GRK2 | |
| SCHEMBL3915705 | 0.84 | MEN1 (0.43) | SMN1; SMN2MEN1KMT2AS1PR5MAPK14 | |
| SCHEMBL3915748 | 0.84 | GRK2 (0.41) | S1PR5ERN1MAPK14METHGF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | SMN1; SMN2 1817/4885TSHR 1695/4885MEN1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.